US biotech giant Moderna is making waves with a new mRNA vaccine in the works, targeting hantavirus—a pathogen that's been quietly wreaking havoc on cruise ships and beyond.
The MV Hondius outbreak has drawn attention to this often-overlooked virus. Hantavirus can be deadly, causing hemorrhagic fever or pulmonary syndrome, but no licensed vaccines exist in Europe, the US or Latin America.
Working closely with South Korea's Vaccine Innovation Center, Moderna hopes to develop a broad-spectrum vaccine that could protect against multiple strains of hantavirus. The mRNA platform offers unique advantages—rapid adaptation and ease of scaling—but the journey from preclinical trials to human trials is long.
Hantaviruses are diverse, with regional variations, making vaccine development complex. However, this international collaboration aims to create a versatile solution that could address global concerns before they become emergencies.
